About Selexis
Selexis is a Healthcare company based in Plan-les-ouates (Switzerland) founded in 2001, and was acquired by JSR Life Sciences in June 2017. Developer of mammalian cell line for the production of recombinant proteins. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Selexis is developing mammalian (suspension-adapted CHO-K1) cell lines using its proprietary technology. Its SURE technology platform claims to facilitate the production of virtually any recombinant protein. It also provides drug discovery and cell line development services.
- Headquarters Plan-les-ouates, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website selexis.com
- Social LinkedIn X
- Acquired by JSR Life Sciences (Jun 2017)
- Investors
- Acquired byJSR Life Sciences
(Jun 2017)
Funding Insights of Selexis
- Total Rounds 1
All 1 funding rounds of Selexis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2015 | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in Selexis
Selexis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include JSR Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Creates innovative technologies for raw materials in biopharmaceutical production. | 2012 | jsrlifesciences.com | Sunnyvale, United States |
Investor details for Selexis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Selexis
6 people are tracked at Selexis (4 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Mark Womack | CEO | Leadership |
Pierre-Alain Girod | Chief Scientific Officer | Leadership |
Roland Hoffmann-Hecht | Chief Business Officer | Leadership |
David Calabrese | Senior Director, Cell Line Services (selexis Fused To KBI Biopharma In April 2023) | Leadership |
Delphine Cloarec | Cell Line Engineer | Team |
Célia de Temmerman | Project Leader, Cell Line Services | Team |
Complete people profiles for Selexis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Selexis
3 dated milestones of Selexis across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Selexis is founded.
- Funding First funding round.
- Exit Acquired by JSR Life Sciences.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Selexis
Complete news archive for Selexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Selexis
Selexis was founded in 2001 and raised its 1st funding round 14 years after it was founded.
Selexis is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
Selexis is developing mammalian (suspension-adapted CHO-K1) cell lines using its proprietary technology. Its SURE technology platform claims to facilitate the production of virtually any recombinant protein. It also provides drug discovery and cell line development services.
Selexis has 1 investor. Key investors include JSR Life Sciences.
Yes. Selexis was acquired by JSR Life Sciences in June 2017.